The Quantellect read.As of Nov 19, 2026, 6 active firms cover Guardian Pharmacy Services, Inc: 6 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $36.00 to $52.00, a moderate spread. The average target of $46.50 sits 5% below the current $48.83. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.29 next quarter toward $1.50 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy6100%
Neutral00%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$46.50
-4.8% downside
Average target across 6 active firms as of Nov 19, 2026 vs $48.83 current
Highest Target$52.00
Average Target$46.50
Lowest Target$36.00
Detailed analyst forecasts for GRDN
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 6 of 6 active firms rate GRDN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
GRDN EPS & revenue forecast
EPS · NEXT QUARTER
$0.29
Range $0.26 – $0.30 · 5 analysts · +0% YoY
Next period, 5 analysts expect Guardian Pharmacy Services, Inc. to earn $0.29 a share (range $0.26 – $0.30), versus $0.29 a year earlier. Full-year consensus is $1.36, growing to $1.50 the year after.
REVENUE · NEXT QUARTER
$362.0M
Range $354.4M – $371.9M · 5 analysts · +8% YoY
Revenue is expected to reach $362.0M (range $354.4M – $371.9M), +7.6% year-over-year. Full-year consensus is $1.5B, rising to $1.6B next year.
Top analysts covering Guardian Pharmacy Services, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GRDN.
#1
DM
David Macdonald
Truist Securities · Rank #111
Buy
$51.00+4.4% to target
Overall win rate
50%
+ Follow
#2
Brian Tanquilut
Jefferies · Rank #280
Buy
$50.00+2.4% to target
Overall win rate
46%
+ Follow
#3
Michael Wiederhorn
Oppenheimer
Buy
$49.00+0.3% to target
Coverage
—
+ Follow
#4
Allen Lutz
B of A Securities
Buy
$47.00-3.7% to target
Coverage
—
+ Follow
#5
RK
Raj Kumar CFA
Stephens
Buy
$36.00-26.3% to target
Coverage
—
+ Follow
GRDN stock forecast FAQ
What is GRDN's average 12-month price target?+
The 6 active firms with a live target average $46.50 for Guardian Pharmacy Services, Inc. over the next 12 months, ranging from a $52.00 high to a $36.00 low, as of Nov 19, 2026.
Is GRDN stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for GRDN?+
The Street-high target is $52.00 (Keybanc), and the Street-low is $36.00 (Stephens & Co.). The average of all 6 active-firm targets is $46.50.
How many active Wall Street firms cover GRDN?+
6 active firms have a recognized rating on Guardian Pharmacy Services, Inc. as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering GRDN?+
Among analysts who currently cover GRDN, David Macdonald of Truist Securities has the strongest overall Quantellect track record (Rank #111). Their current call is Buy with a $51.00 target.
What is Guardian Pharmacy Services, Inc.'s projected EPS for next quarter?+
The consensus estimate is $0.29 per share (range $0.26 – $0.30) across 5 analysts. Full-year EPS is projected at $1.36, rising to $1.50 the following year.
How much revenue is Guardian Pharmacy Services, Inc. expected to report next quarter?+
Consensus revenue is $362.0M (range $354.4M – $371.9M). Full-year revenue is projected at $1.5B, growing to $1.6B next year.
Have analysts been upgrading or downgrading GRDN lately?+
As of Nov 19, 2026, 6 of 6 active firms rate GRDN a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GRDN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.